Jeong JH - Search Results

1

Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor.

Jeong JH, Cho BC, Shim HS, Kim HR, Lim SM, Kim SK, Chung KY, Ul Islam SM, Song JJ, Kim SY, Kim JH. Jeong JH, et al. J Korean Med Sci. 2013 Jul;28(7):1005-14. doi: 10.3346/jkms.2013.28.7.1005. Epub 2013 Jul 3. J Korean Med Sci. 2013. PMID: 23853482 Free PMC article.

2

Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.

Kim GM, Kim YS, Ae Kang Y, Jeong JH, Kim SM, Hong YK, Sung JH, Lim ST, Kim JH, Kim SK, Cho BC. Kim GM, et al. Among authors: jeong jh. J Thorac Oncol. 2012 Apr;7(4):731-6. doi: 10.1097/JTO.0b013e31824b23cb. J Thorac Oncol. 2012. PMID: 22425922 Free article.

3

Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.

Jeong J, Cho BC, Sohn JH, Choi HJ, Kim SH, Lee YJ, Jung MK, Shin SJ, Park MS, Kim SK, Chang J, Kim JH. Jeong J, et al. Lung Cancer. 2010 Oct;70(1):77-81. doi: 10.1016/j.lungcan.2010.01.006. Epub 2010 Mar 16. Lung Cancer. 2010. PMID: 20138389 Clinical Trial.

4

A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.

Heo SJ, Jung I, Lee CK, Kim JH, Lim SM, Moon YW, Shim HS, Jeong J, Kim JH, Kim HR, Cho BC. Heo SJ, et al. Among authors: jeong j. Cancer Chemother Pharmacol. 2016 Mar;77(3):539-48. doi: 10.1007/s00280-016-2968-z. Epub 2016 Jan 25. Cancer Chemother Pharmacol. 2016. PMID: 26811178 Clinical Trial.

5

A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).

Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK, Sung JH, Ha SJ, Kim HR, Chang H, Kim JH, Tania C, Cho BC. Kim SH, et al. Among authors: jeong jh. Lung Cancer. 2013 Mar;79(3):270-5. doi: 10.1016/j.lungcan.2012.11.017. Epub 2012 Dec 20. Lung Cancer. 2013. PMID: 23261229 Clinical Trial.

6

Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer.

Choi CM, Jang SJ, Park SY, Choi YB, Jeong JH, Kim DS, Kim HK, Park KS, Nam BH, Kim HR; Korean Thoracic Oncology Research Group (KTORG); Kim SY, Hong KM. Choi CM, et al. Among authors: jeong jh. Mol Cancer. 2011 Sep 24;10:119. doi: 10.1186/1476-4598-10-119. Mol Cancer. 2011. PMID: 21943122 Free PMC article.

7

Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer.

Moon YW, Sohn JH, Kim YT, Chang H, Jeong JH, Lee YJ, Chang J, Kim SK, Jung M, Hong S, Choi SH, Kim JH. Moon YW, et al. Among authors: jeong jh. Anticancer Res. 2009 Oct;29(10):4243-9. Anticancer Res. 2009. PMID: 19846981 Free article.

8

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13.

Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Yoo KH, et al. Among authors: jeong j. Cancer Res Treat. 2019 Apr;51(2):718-726. doi: 10.4143/crt.2018.324. Epub 2018 Sep 3. Cancer Res Treat. 2019. PMID: 30177585 Free PMC article. Clinical Trial.

9

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).

Kim YR, Kim JS, Min YH, Hyunyoon D, Shin HJ, Mun YC, Park Y, Do YR, Jeong SH, Park JS, Oh SY, Lee S, Park EK, Jang JS, Lee WS, Lee HW, Eom H, Ahn JS, Jeong JH, Baek SK, Kim SJ, Kim WS, Suh C. Kim YR, et al. Among authors: jeong sh, jeong jh. J Hematol Oncol. 2012 Aug 13;5:49. doi: 10.1186/1756-8722-5-49. J Hematol Oncol. 2012. PMID: 22889180 Free PMC article.

10

Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.

Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, Roh JK, Rha SY. Hong S, et al. Oncology. 2011;80(1-2):107-17. doi: 10.1159/000327216. Epub 2011 Jun 14. Oncology. 2011. PMID: 21677455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,678 results

Search Page

Filters